Current and future role of PCSK9 inhibitors in ASCVD prevention.
作者信息
Greco Antonio, Capodanno Davide
机构信息
Azienda Ospedaliero-Universitaria Policlinico "G. Rodolico - San Marco", University of Catania, Catania, Italy.
出版信息
Future Cardiol. 2025 Feb;21(2):71-73. doi: 10.1080/14796678.2025.2450189. Epub 2025 Jan 5.
Abstract
摘要
相似文献
1
Current and future role of PCSK9 inhibitors in ASCVD prevention.前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂在动脉粥样硬化性心血管疾病（ASCVD）预防中的当前及未来作用
Future Cardiol. 2025 Feb;21(2):71-73. doi: 10.1080/14796678.2025.2450189. Epub 2025 Jan 5.
2
Cutting-edge lipid-lowering pharmacological therapies: Improving lipid control beyond statins.前沿降脂药物疗法：超越他汀类药物改善血脂控制。
Hipertens Riesgo Vasc. 2025 Apr-Jun;42(2):116-127. doi: 10.1016/j.hipert.2024.12.002. Epub 2025 Jan 6.
3
Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia: A systematic review and meta-analysis.前蛋白转化酶枯草溶菌素9单克隆抗体在他汀类药物无反应的高胆固醇血症和血脂异常患者中的治疗效果：一项系统评价和荟萃分析。
Int J Cardiol. 2016 Nov 1;222:119-129. doi: 10.1016/j.ijcard.2016.07.239. Epub 2016 Jul 30.
4
2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.2017 年对 2016 年美国心脏病学会专家共识决策途径的重点更新：非他汀类药物在降低动脉粥样硬化性心血管疾病风险管理中的作用：美国心脏病学会专家组的专家共识决策途径报告。
J Am Coll Cardiol. 2017 Oct 3;70(14):1785-1822. doi: 10.1016/j.jacc.2017.07.745. Epub 2017 Sep 5.
5
Inadequate awareness and attention to non-HDL cholesterol: undertreatment of high-risk patients in cardiology practice in Turkey.对非高密度脂蛋白胆固醇认识不足及关注不够：土耳其心脏病学实践中高危患者的治疗不足。
Coron Artery Dis. 2025 Aug 1;36(5):396-405. doi: 10.1097/MCA.0000000000001493. Epub 2025 Jan 20.
6
Proposed low-density lipoprotein cholesterol goals for secondary prevention and familial hypercholesterolemia in India with focus on PCSK9 inhibitor monoclonal antibodies: Expert consensus statement from Lipid Association of India.印度针对二级预防和家族性高胆固醇血症的低密度脂蛋白胆固醇目标建议：聚焦前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂单克隆抗体——来自印度脂质协会的专家共识声明
J Clin Lipidol. 2020 Mar-Apr;14(2):e1-e13. doi: 10.1016/j.jacl.2020.01.006. Epub 2020 Jan 24.
7
Role of Different Low-Density Lipoprotein-Lowering Medications on Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients With Diabetes Mellitus.不同降低低密度脂蛋白药物在糖尿病患者动脉粥样硬化性心血管疾病二级预防中的作用
Cureus. 2023 Jun 24;15(6):e40905. doi: 10.7759/cureus.40905. eCollection 2023 Jun.
8
Cardiovascular risk management beyond statins: review of new therapies available in Italy.他汀类药物之外的心血管风险管理：意大利可用新疗法综述
Egypt Heart J. 2025 Jul 1;77(1):68. doi: 10.1186/s43044-025-00660-0.
9
Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 35 Randomized Controlled Trials.PCSK9 抑制剂对高胆固醇血症患者临床结局的影响：35 项随机对照试验的荟萃分析。
J Am Heart Assoc. 2017 Dec 9;6(12):e006910. doi: 10.1161/JAHA.117.006910.
本文引用的文献
1
Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects.脂蛋白(a)作为一种药理学靶点：前提、前景与展望。
Circulation. 2025 Feb 11;151(6):400-415. doi: 10.1161/CIRCULATIONAHA.124.069210. Epub 2025 Feb 10.
2
P2Y12 Inhibitor Monotherapy: Considerations for Acute and Long-Term Secondary Prevention Post-PCI.P2Y12抑制剂单药治疗：PCI术后急性和长期二级预防的考量
Rev Cardiovasc Med. 2022 Oct 17;23(10):348. doi: 10.31083/j.rcm2310348. eCollection 2022 Oct.
3
Sodium-Glucose Cotransporter-2 Inhibitors: Elevating Standards in Cardiovascular Secondary Prevention.钠-葡萄糖协同转运蛋白2抑制剂：提升心血管二级预防标准
Am J Cardiovasc Drugs. 2024 Sep;24(5):625-628. doi: 10.1007/s40256-024-00666-0. Epub 2024 Jul 17.
4
Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial.利洛昔班治疗或有心血管疾病风险患者的疗效和安全性：一项随机临床试验。
JAMA Cardiol. 2024 Sep 1;9(9):800-807. doi: 10.1001/jamacardio.2024.1659.
5
PCSK9 inhibitors: current status and emerging frontiers in lipid control.PCSK9 抑制剂：血脂控制的现状与新前沿。
Expert Rev Cardiovasc Ther. 2024 Jan-Mar;22(1-3):41-58. doi: 10.1080/14779072.2023.2288169. Epub 2023 Nov 28.
6
Complete Percutaneous Coronary Revascularization in Acute Coronary Syndromes With Multivessel Coronary Disease: A Systematic Review.多支冠状动脉疾病急性冠脉综合征的完全经皮冠状动脉血运重建：一项系统评价
JACC Cardiovasc Interv. 2023 Oct 9;16(19):2347-2364. doi: 10.1016/j.jcin.2023.07.043.
7
Novel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease.动脉粥样硬化性心血管疾病的新型治疗靶点与新兴治疗方法
Eur Heart J Cardiovasc Pharmacother. 2024 Jan 5;10(1):53-67. doi: 10.1093/ehjcvp/pvad074.
8
Antithrombotic Therapy for Primary and Secondary Prevention of Ischemic Stroke: JACC State-of-the-Art Review.抗血栓治疗用于缺血性卒中原发和二级预防：JACC 现状评价。
J Am Coll Cardiol. 2023 Oct 10;82(15):1538-1557. doi: 10.1016/j.jacc.2023.07.025.
9
Eligibility to Intensified Antithrombotic Regimens for Secondary Prevention in Patients Who Underwent Percutaneous Coronary Intervention.经皮冠状动脉介入治疗患者强化抗血栓治疗方案的选择用于二级预防。
Am J Cardiol. 2023 Jul 15;199:7-17. doi: 10.1016/j.amjcard.2023.04.036. Epub 2023 May 20.
10
Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616.MK-0616 口服 PCSK9 抑制剂的 2b 期随机试验。
J Am Coll Cardiol. 2023 Apr 25;81(16):1553-1564. doi: 10.1016/j.jacc.2023.02.018. Epub 2023 Mar 6.
Zotero 插件